Free tools Windows power users keep installed
One-click scans. No signup required.
Proximity-driven metallopeptide catalysis uses a designed peptide to bring a dirhodium catalyst close to a selected region of a protein. A broadly reactive diazo reagent then modifies nearby side chains. The approach can steer a reaction through molecular recognition rather than relying on a reagent that recognizes only one amino acid—but the published results are specific laboratory demonstrations, not a universal or routine protein-editing method.
How the close-encounter method works
Protein modification is difficult to direct when the same reactive amino acid appears at multiple positions. In this method, a substrate peptide and a dirhodium metallopeptide catalyst assemble through coiled-coil interactions. That recognition brings the catalyst near a chosen protein region. Researchers then add a diazo reagent, which reacts with nearby side chains.
As an Amazon Associate I earn from qualifying purchases.
The design shifts the source of selectivity: the reagent need not be highly selective if the catalyst is localized near the intended region. The Royal Society of Chemistry’s 2011 account describes the reagent as a diazo derivative of styrene and says catalytic units that are not appropriately localized are rapidly destroyed by reaction with water. The primary study describes the approach as modification based on molecular shape.
What the studies demonstrated
| Study | What it tested or reported | Conditions or biological context |
|---|---|---|
| 2010 JACS study | Focused on aromatic side chains and coil structures; reported selective chemical modification of phenylalanine and a rate enhancement greater than 103 relative to nonselective dirhodium modification. | The cited account does not state a biological matrix for this result. |
| 2011 Chemical Science study | Reported a broader range of modified amino-acid side chains, including the first examples of carboxamide modification of glutamine and asparagine. It demonstrated covalent modification of the c-Fos bZip domain at different residues depending on metallopeptide structure. | The cited report establishes the c-Fos bZip domain demonstration; it does not establish universal performance across proteins. |
| 2011 ACS Chemical Biology follow-up | Extended the approach to physiological pH and biologically relevant buffers, reported specific modification in E. coli lysate, and used a biotin-diazo conjugate for affinity tagging. | Biologically relevant buffers and E. coli lysate were tested; the report does not establish clinical use. |
The 2011 Royal Society of Chemistry news account summarized the side-chain scope as “over half” of naturally occurring amino-acid types. That is the account’s characterization of the reported chemical scope, not a measure of how many proteins can be modified selectively.
#1 Best Overall
What determines where modification occurs
Selectivity comes from the relationship between the designed recognition peptide, the coiled-coil assembly, and the protein region being targeted. The 2011 Chemical Science study’s finding that the c-Fos bZip domain was modified at different residues depending on metallopeptide structure illustrates that changing the recognition design can change the site of modification.
This is not simply a matter of adding a catalyst and expecting it to find a unique amino acid. The recognition element must assemble in a way that positions the catalyst near the desired region, and the reaction occurs in the context of that designed molecular encounter.
Rank #2
What “easy” does—and does not—mean
The headline phrase refers to a useful design principle: localizing a broadly reactive catalyst can make targeted modification possible without requiring a uniquely selective reagent. It does not mean the process is trivial, works on every protein, or is available as an off-the-shelf service or product. The cited studies establish experiments with particular catalyst designs, substrates, and conditions.
- Established: published examples of residue modification, including work on the c-Fos bZip domain, and a follow-up demonstration in E. coli lysate.
- Not established by these studies: universal site selectivity, routine adoption across laboratories, clinical benefit, or a human disease treatment.
Zachary T. Ball, the corresponding author, described transient protein interactions in disease-related signaling pathways as a possible area for future investigation in the RSC’s 2011 account. That was a prospective research application, not a reported clinical outcome.
Quick Recap
Rank #4
Rank #3
Read the original studies and account
- Popp and Ball, “Proximity-driven metallopeptide catalysis,” Chemical Science (2011).
- Popp and Ball, “Structure-Selective Modification of Aromatic Side Chains with Dirhodium Metallopeptide Catalysts,” JACS (2010).
- Chen, Popp, Bovet, and Ball, “Site-Specific Protein Modification with a Dirhodium Metallopeptide Catalyst,” ACS Chemical Biology (2011).
- Royal Society of Chemistry’s 2011 account of the work.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
